Clinical trial
Use of NovoSeven® in Active Variceal Bleeding
NCT00154492 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00154492 |
|---|---|
| Title | Use of NovoSeven® in Active Variceal Bleeding |
| Official title | Effectiveness and Safety of Use of NovoSeven® in the Treatment of Active Variceal Bleeding in Patients With Advanced Cirrhosis |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acquired Bleeding Disorder, Cirrhosis |
| Intervention type | Drug |
| Interventions | activated recombinant human factor VII |
| Enrollment | 265 |
| Start date | Apr 1, 2004 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 13, 2017 |
| Countries | Austria, Czechia, Denmark, Finland, France, Germany, Hong Kong, Italy, Poland, Spain, Taiwan, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: